NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/28/2024
Back to search
Official data from USPTO
YOCHANRA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
05/28/2024
Trademark type
Combined
Nice classes
5
Filing date
06/03/2022
Registration date
05/28/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/28/2024
Last transaction
05/28/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
3
Owner type
03
Owner location
Nanjing, Jiangsu, CN
Examiner
MAYES, LAURIE ANN
Law office
L10
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of a spherical design formed by three stacked offset curved lines on the bottom and three stacked offset curved dotted lines on the top with the word "YOCHANRA" to the right of the design.
Holders and representatives
Holders
TransThera Sciences (Nanjing), Inc.
Representatives
Michael T. Smith Birch Stewart Kolasch & Birch, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; pharmaceutical preparations for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; drugs for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemico-pharmaceutical preparations for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemical preparations for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; biological preparations for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; bulk medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; biochemical medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemical preparations for pharmaceutical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; medicines in the nature of tablets for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; medicines for human purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders in the nature of capsule; injectable medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders
Publications
History of USPTO decisions and trademark events.
34 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/28/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/12/2024
PUBO
PUBLISHED FOR OPPOSITION
03/12/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/21/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/21/2024
IUCN
NOTICE OF ALLOWANCE CANCELLED
02/08/2024
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
02/07/2024
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
02/07/2024
APET
ASSIGNED TO PETITION STAFF
02/06/2024
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
01/10/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/12/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/09/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/09/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/09/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/09/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/09/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/17/2023
PUBO
PUBLISHED FOR OPPOSITION
10/17/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/27/2023
WOAG
WITHDRAWAL OF ATTORNEY GRANTED
09/12/2023
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
09/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/28/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/28/2023
ALIE
ASSIGNED TO LIE
08/28/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/14/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/03/2023
GNRT
NON-FINAL ACTION E-MAILED
03/03/2023
CNRT
NON-FINAL ACTION WRITTEN
03/03/2023
DOCK
ASSIGNED TO EXAMINER
02/25/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/14/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/13/2022
NWAP
NEW APPLICATION ENTERED
06/07/2022
Continuous trademark protection
Get notified about every new filing that threatens YOCHANRA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.